A case for measuring both cellular and cell-free mitochondrial DNA as a disease biomarker in human blood.
absolute quantification
circulating nucleic acids
inflammation
mitochondria
qPCR
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
28
04
2020
revised:
26
06
2020
accepted:
30
06
2020
pubmed:
31
7
2020
medline:
17
3
2021
entrez:
31
7
2020
Statut:
ppublish
Résumé
Circulating mitochondrial DNA (mtDNA), widely studied as a disease biomarker, comprises of mtDNA located within mitochondria, indicative of mitochondrial function, and cell-free (cf) mtDNA linked to inflammation. The purpose of this study was to determine the ranges of, and relationship between, cellular and cf mtDNA in human blood. Whole blood from 23 controls (HC) and 20 patients with diabetes was separated into peripheral blood mononuclear cells (PBMCs), plasma, and serum. Total DNA was isolated and mtDNA copy numbers were determined using absolute quantification. Cellular mtDNA content in PBMCs was higher than in peripheral blood and a surprisingly high level of cf mtDNA was present in serum and plasma of HC, with no direct relationship between cellular and cf mtDNA content within individuals. Diabetes patients had similar levels of cellular mtDNA compared to healthy participants but a significantly higher cf mtDNA content. Furthermore, only in patients with diabetes, we observed a correlation between whole blood and plasma mtDNA levels, indicating that the relationship between cellular and cf mtDNA content is affected by disease status. In conclusion, when evaluating mtDNA in human blood as a biomarker of mitochondrial dysfunction, it is important to measure both cellular and cf mtDNA.
Identifiants
pubmed: 32729179
doi: 10.1096/fj.202000959RR
doi:
Substances chimiques
Biomarkers
0
Cell-Free Nucleic Acids
0
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12278-12288Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Shoubridge EA, Wai T. Mitochondrial DNA and the mammalian oocyte. Curr Top Dev Biol. 2007;77:87-111.
Miller FJ, Rosenfeldt FL, Zhang C, Linnane AW, Nagley P. Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age. Nucleic Acids Res. 2003;31:e61.
Lan Q, Lim U, Liu C-S, et al. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. Blood. 2008;112:4247-4249.
Lightowlers RN, Chinnery PF, Turnbull DM, Howell N. Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet. 1997;13:450-455.
Cao H, Wu J, Luo J, Chen X, Yang J, Fang L. Urinary mitochondrial DNA: A potential early biomarker of diabetic nephropathy. Diabetes Metab Res Rev. 2019;35:e3131.
Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013;13:481-492.
Afrifa J, Zhao T, Yu J. Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate. Mitochondrion. 2019;47:238-243.
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 1999;23:147.
Reinecke F, Smeitink JAM, van der Westhuizen FH. OXPHOS gene expression and control in mitochondrial disorders. Biochim Biophys Acta. 2009;1792:1113-1121.
Riley JS, Tait SW. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 2020;21:e49799.
McCarthy CG, Wenceslau CF, Goulopoulou S, et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res. 2015;107:119-130.
Zhong F, Liang S, Zhong Z. Emerging role of mitochondrial DNA as a major driver of inflammation and disease progression. Trends Immunol. 2019;40:1120-1133.
Bae JH, Jo SI, Kim SJ, et al. Circulating cell-free mtDNA contributes to AIM2 inflammasome-mediated chronic inflammation in patients with type 2 diabetes. Cells. 2019;8(4):328.
Knez J, Marrachelli VG, Cauwenberghs N, et al. Peripheral blood mitochondrial DNA content in relation to circulating metabolites and inflammatory markers: a population study. PLoS One. 2017;12:e0181036.
Ashar FN, Moes A, Moore AZ, et al. Association of mitochondrial DNA levels with frailty and all-cause mortality. J Mol Med. 2015;93:177-186.
Tripathi S, Kumar YVB, Agrawal A, Prabhakar A, Joshi SS. Microdevice for plasma separation from whole human blood using bio-physical and geometrical effects. Sci Rep. 2016;6:26749.
Cicchillitti L, Corrado G, De Angeli M, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget. 2017;8:115230-115243.
Pyle A, Brennan R, Kurzawa-Akanbi M, et al. Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. Ann Neurol. 2015;78:1000-1004.
Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol. 2013;74:655-668.
Lowes H, Pyle A, Duddy M, Hudson G. Cell-free mitochondrial DNA in progressive multiple sclerosis. Mitochondrion. 2019;46:307-312.
Stertz L, Fries GR, Rosa AR, et al. Damage-associated molecular patterns and immune activation in bipolar disorder. Acta Psychiatr Scand. 2015;132:211-217.
Nakahira K, Kyung S-Y, Rogers AJ, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 2013;10:e1001577.
Thurairajah K, Briggs GD, Balogh ZJ. The source of cell-free mitochondrial DNA in trauma and potential therapeutic strategies. Eur J Trauma Emerg Surg. 2018;44:325-334.
Biró O, Hajas O, Nagy-Baló E, Soltész B, Csanádi Z, Nagy B. Relationship between cardiovascular diseases and circulating cell-free nucleic acids in human plasma. Biomark Med. 2018;12:891-905.
Czajka A, Ajaz S, Gnudi L, et al. Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy. EBioMedicine. 2015;2:499-512.
Malik AN, Parsade CK, Ajaz S, et al. Altered circulating mitochondrial DNA and increased inflammation in patients with diabetic retinopathy. Diabetes Res Clin Pract. 2015;110:257-265.
Rykova E, Sizikov A, Roggenbuck D, et al. Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther. 2017;19:85.
Udomsinprasert W, Poovorawan Y, Chongsrisawat V, Vejchapipat P, Jittikoon J, Honsawek S. Leukocyte mitochondrial DNA copy number as a potential biomarker indicating poor outcome in biliary atresia and its association with oxidative DNA damage and telomere length. Mitochondrion. 2019;47:1-9.
Workalemahu T, Enquobahrie DA, Tadesse MG, et al. Genetic variations related to maternal whole blood mitochondrial DNA copy number: a genome-wide and candidate gene study. J Matern Fetal Neonatal Med. 2017;30:2433-2439.
Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern released during active IBD. Inflamm Bowel Dis. 2018;24:2113-2122.
Cao H, Ye H, Sun Z, et al. Circulatory mitochondrial DNA is a pro-inflammatory agent in maintenance hemodialysis patients. PLoS One. 2014;9:e113179.
Kumar M, Srivastava S, Singh SA, et al. Cell-free mitochondrial DNA copy number variation in head and neck squamous cell carcinoma: a study of non-invasive biomarker from Northeast India. Tumor Biol. 2017;39:1010428317736643.
Malik AN, Shahni R, Rodriguez-de-Ledesma A, Laftah A, Cunningham P. Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem Biophys Res Comm. 2011;412:1-7.
Ajaz S, Czajka A, Malik A. Accurate measurement of circulating mitochondrial DNA content from human blood samples using real-time quantitative PCR. Methods Mol Biol. 2015;1264:117-131.
Qin C, Gu J, Liu R, et al. Release of mitochondrial DNA correlates with peak inflammatory cytokines in patients with acute myocardial infarction. Anatol J Cardiol. 2017;17:224-228.
Bianco A, Valletti A, Longo G, et al. Mitochondrial DNA copy number in affected and unaffected LHON mutation carriers. BMC Res Notes. 2018;11:911.
Malik AN, Rosa HS. Potential mechanisms of mitochondrial DNA mediated acquired mitochondrial disease. In: Oliveira PJ, ed. Mitochondrial Biology and Experimental Therapeutics. Cham: Springer International Publishing; 2018:297-315.
Grady JP, Pickett SJ, Ng YS, et al. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Mol Med. 2018;10:e8262.
Chacko BK, Kramer PA, Ravi S, et al. The Bioenergetic Health Index: a new concept in mitochondrial translational research. Clin Sci (Lond). 2014;127:367-373.
Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis. 2003;16:5-10.
Urata M, Koga-Wada Y, Kayamori Y, Kang D. Platelet contamination causes large variation as well as overestimation of mitochondrial DNA content of peripheral blood mononuclear cells. Ann Clin Biochem. 2008;45:513-514.
Hurtado-Roca Y, Ledesma M, Gonzalez-Lazaro M, et al. Adjusting MtDNA quantification in whole blood for peripheral blood platelet and leukocyte counts. PLoS One. 2016;11:e0163770.
Picard M, Prather AA, Puterman E, et al. A mitochondrial health index sensitive to mood and caregiving stress. Biol Psychiatry. 2018;84:9-17.
Casula M, Weverling GJ, Wit FW, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis. 2005;192:1794-1800.
Yang Y, Yang J, Yu B, et al. Association between circulating mononuclear cell mitochondrial DNA copy number and in-hospital mortality in septic patients: a prospective observational study based on the Sepsis-3 definition. PLoS One. 2019;14:e0212808.
Longchamps R, Castellani C, Newcomb C, et al. Evaluation of mitochondrial DNA copy number estimation techniques. bioRxiv. 2019:610238.
Lei L, Guo J, Shi X, et al. Mitochondrial DNA copy number in peripheral blood cell and hypertension risk among mining workers: a case-control study in Chinese coal miners. J Hum Hypertens. 2017;31:585-590.
Arshad O, Gadawska I, Sattha B, Cote HCF, Hsieh AYY. Elevated cell-free mitochondrial DNA in filtered plasma is associated with HIV infection and inflammation. J Acquir Immune Defic Syndr (1999). 2018;78:111-118.
Dai Z, Cai W, Hu F, et al. Plasma mitochondrial DNA levels as a biomarker of lipodystrophy among HIV-infected patients treated with highly active antiretroviral therapy (HAART). Curr Mol Med. 2015;15:975-979.
Zhang R, Nakahira K, Guo X, Choi AMK, Gu Z. Very short mitochondrial DNA fragments and heteroplasmy in human plasma. Sci Rep. 2016;6:36097.
Al Amir Dache Z, Otandault A, Tanos R, et al. Blood contains circulating cell-free respiratory competent mitochondria. FASEB J. 2020;34:3616-3630.
Jiang P, Chan CWM, Chan KCA, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112:E1317-E1325.
Catano Canizales YG, Uresti Rivera EE, Garcia Jacobo RE, et al. Increased levels of AIM2 and circulating mitochondrial DNA in type 2 diabetes. Iran J Immunol. 2018;15:142-155.
Harrington JS, Huh JW, Schenck EJ, Nakahira K, Siempos II, Choi AMK. Circulating mitochondrial DNA as predictor of mortality in critically Ill patients: a systematic review of clinical studies. Chest. 2019;156:1120-1136.
Silzer T, Barber R, Sun J, et al. Circulating mitochondrial DNA: new indices of type 2 diabetes-related cognitive impairment in Mexican Americans. PLoS One. 2019;14:e0213527.
Liu J, Cai X, Xie L, et al. Circulating cell free mitochondrial DNA is a biomarker in the development of coronary heart disease in the patients with type 2 diabetes. Clin Lab. 2015;61:661-667.